Follow The Filings

LBRX LB Pharmaceuticals Inc.

Health Care, filed as LB PHARMACEUTICALS INC (COM SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 James Silverman sold out of LB Pharmaceuticals.

Who owns LBRX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 0.05% Exit −0.05% 14,506 $358K History

Weight bar: held both quarters added sold at this quarter’s reported price

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
424B3
8-K 5.02,7.01,9.01
8-K 5.02,7.01,9.01
424B3
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
424B3
SCHEDULE 13G/A —
8-K 1.01,3.02,7.01,9.01
424B3
8-K 8.01,9.01
424B3
SCHEDULE 13G —
8-K 5.02,9.01
424B3
8-K 5.07
424B3
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q

Insider forms

Forms 3, 4 and 5 from EDGAR, 3 rows shown

Filed Form Detail Links
4 Period Oct 9, 2026 (2 forms)
4 Period Jul 30, 2026
4 Period Jun 3, 2026 (7 forms)

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2025
Net income -$25.2M

Balance sheet

Metric FY2025
Total current assets $308.43M
Total non-current assets * $4.5M
Total assets $312.93M
Total current liabilities $7.44M
Total non-current liabilities * $4.18M
Total equity $301.31M

Cash flow

Metric FY2025
Cash from operations -$35.21M
Cash from investing -$39.89M
Cash from financing $302.56M
Net change in cash $227.47M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Period archive